Lv1
30 积分 2025-07-08 加入
One-year functional and structural effects of mavacamten in obstructive hypertrophic cardiomyopathy: a comprehensive CMR study
8个月前
已完结
In vitroandin vivopharmacokinetic characterization of mavacamten, a first-in-class small molecule allosteric modulator of beta cardiac myosin
9个月前
已完结
In vitro and in vivo preclinical pharmacokinetic characterization of aficamten, a small molecule cardiac myosin inhibitor
9个月前
已完结
Computational Predictions of Nonclinical Pharmacokinetics at the Drug Design Stage
9个月前
已完结
EDG-7500, A First-in-Class Cardiac Sarcomere Modulator, Demonstrates Favorable Tolerability, Safety, And Pharmacokinetics In Healthy Adults
9个月前
已完结
Aficamten in the treatment of obstructive hypertrophic cardiomyopathy
9个月前
已完结
Organoids and organs-on-chips: Recent advances, applications in drug development, and regulatory challenges
10个月前
已完结
In vitroandin vivopharmacokinetic characterization of mavacamten, a first-in-class small molecule allosteric modulator of beta cardiac myosin
10个月前
已完结
In vitro and in vivo preclinical pharmacokinetic characterization of aficamten, a small molecule cardiac myosin inhibitor
10个月前
已完结
In vitro and in vivo preclinical pharmacokinetic characterization of aficamten, a small molecule cardiac myosin inhibitor
10个月前
已完结
皖公网安备34019202002308
